Survival of Patients With Cancer With <i>DPYD</i> Variant Alleles and Dose-Individualized Fluoropyrimidine Therapy—A Matched-Pair Analysis-Reference-Cited by-同舟云学术

Survival of Patients With Cancer With DPYD Variant Alleles and Dose-Individualized Fluoropyrimidine Therapy—A Matched-Pair Analysis

Published:2023-12-10 Issue:35 Volume:41 Page:5411-5421
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Knikman Jonathan E.¹²^ORCID,Wilting Tycho A.¹^ORCID,Lopez-Yurda Marta³^ORCID,Henricks Linda M.⁴,Lunenburg Carin A.T.C.⁵,de Man Femke M.⁶,Meulendijks Didier¹⁷⁸,Nieboer Peter⁹,Droogendijk Helga J.¹⁰,Creemers Geert-Jan¹¹^ORCID,Mandigers Caroline M.P.W.¹²,Imholz Alexander L.T.¹³,Mathijssen Ron H.J.⁶^ORCID,Portielje Johanneke E.A.⁵¹⁴^ORCID,Valkenburg-van Iersel Liselot¹⁵^ORCID,Vulink Annelie¹⁶,van der Poel Marlene H.W.¹⁷,Baars Arnold¹⁸^ORCID,Swen Jesse J.¹⁹^ORCID,Gelderblom Hans⁵^ORCID,Schellens Jan H.M.²⁰,Beijnen Jos H.²²¹^ORCID,Guchelaar Henk-Jan¹⁹^ORCID,Cats Annemieke²²

Affiliation:

1. Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands

2. Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands

3. Biometrics Department, The Netherlands Cancer Institute, Amsterdam, the Netherlands

4. Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, the Netherlands

5. Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands

6. Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands

7. Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands

8. Late Development Oncology, AstraZeneca, Cambridge, UK

9. Department of Internal Medicine, Wilhelmina Hospital Assen, Assen, the Netherlands

10. Department of Internal Medicine, Bravis Hospital, Roosendaal, the Netherlands

11. Department of Medical Oncology, Catharina Hospital, Eindhoven, the Netherlands

12. Department of Internal Medicine, Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands

13. Department of Internal Medicine, Deventer Hospital, Deventer, the Netherlands

14. Department of Medical Oncology, Haga Hospital, The Hague, the Netherlands

15. Department of Internal Medicine, Maastricht University Medical Center, Maastricht, the Netherlands

16. Department of Medical Oncology, Reinier de Graaf Gasthuis, Delft, the Netherlands

17. Department of Internal Medicine, Laurentius Hospital, Roermond, the Netherlands

18. Department of Internal Medicine, Hospital Gelderse Vallei, Ede, the Netherlands

19. Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands

20. Department of Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands

21. Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands

22. Department of Gastrointestinal Oncology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands

Abstract

Outcome of DPYD variant allele carriers treated with dose-individualized fluoropyrimidine therapy.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.22.02780

Reference19 articles.

1. 5-Fluorouracil: mechanisms of action and clinical strategies

2. Clinical Pharmacology of 5-Fluorouracil

3. Individualized Dosing of Fluoropyrimidine‐Based Chemotherapy to Prevent Severe Fluoropyrimidine‐Related Toxicity: What Are the Options?

4. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real‐world implementation of DPYD and UGT1A1 pharmacogenetic testing in a community‐based cancer center;Clinical and Translational Science;2024-01-26

2. Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis;British Journal of Cancer;2024-01-15

3. Updated DPYDHapB3 haplotype structure and implications for pharmacogenomic testing;Clinical and Translational Science;2024-01

4. Implementation of pre‐emptive testing of a pharmacogenomic panel in clinical practice: Where do we stand?;British Journal of Clinical Pharmacology;2023-12-21